Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO +1.36%53 PB Ratio is 0.85 as of Jul. 29, 2026, which is 62% below its 10-year median of 2.26. GuruFocus rates SILO with a GF Score™ of 53/100 and a GF Value™ of $5.16 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, SILO Pharma ranks better than 84.52% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-29), SILO Pharma's share price is $4.46. SILO Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $5.24. Hence, SILO Pharma's PB Ratio of today is 0.85.
The historical rank and industry rank for SILO Pharma's PB Ratio or its related term are showing as below:
SILO'
s PB Ratio Range Over the Past 10 Years
Min: 0.48 Med: 2.26 Max: 83.29
Current: 0.85
During the past 13 years, SILO Pharma's highest PB Ratio was 83.29. The lowest was 0.48. And the median was 2.26.
SILO's PB Ratio is ranked better than 84.52% of 1227
companies
in the Biotechnology industry
Industry Median: 2.75
vs SILO: 0.85
During the past 12 months, SILO Pharma's average Book Value Per Share Growth Rate was -60.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -47.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -18.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of SILO Pharma was 206.90% per year. The lowest was -47.50% per year. And the median was -20.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
SILO Pharma PB Ratio Related Terms
SILO Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for SILO Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SILO Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where SILO Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
SILO Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
SILO Pharma (SILO) has a PB Ratio of 0.85 as of Jul. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SILO Pharma and its competitors. This is 62% below median its historical median of 2.26. Over the past decade, SILO Pharma's PB Ratio has ranged from 0.48 to 83.29. According to the industry distribution chart, SILO Pharma ranks #190 out of 1227 companies in the Biotechnology industry, placing it in the top 15.5%.
Is SILO Pharma's PB Ratio too high?
SILO Pharma's current PB Ratio of 0.85 is 62% below median its 10-year median of 2.26. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 83.29. The Biotechnology industry median PB Ratio is 2.75. SILO Pharma's value of 0.85 is 69.1% below this industry median. Based on the distribution chart, SILO Pharma ranks #190 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SILO Pharma has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's PB Ratio compare to ALZN and BGMS?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #190 out of 1227 companies for PB Ratio. This places SILO Pharma in the top 16% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.75. SILO Pharma's value of 0.85 is 69.1% below this benchmark. Historically, SILO Pharma's own PB Ratio has ranged from 0.48 to 83.29 over the past decade. While the company's 10-year median is 2.26 vs. the industry median of 2.75, SILO Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.75, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SILO Pharma's current PB Ratio of 0.85 is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SILO Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SILO Pharma's current PB Ratio is 0.85, which is 62% below median its own 10-year median of 2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.16, compared to a current price of $4.46 — trading 13.6% below its estimated fair value. The current PB Ratio is 0.85, which is 62% below median its 10-year median of 2.26 and 69.1% below the Biotechnology industry median of 2.75. SILO Pharma's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For SILO Pharma (SILO), the current PB Ratio is 0.85 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $4.46 is trading 13.6% below its estimated GF Value™ of $5.16.
GuruFocus considers SILO Pharma to be Modestly Undervalued.
Key valuation signals for SILO:
PB Ratio: 0.85 (62% below median its 10-year median of 2.26)
GF Value™: $5.16 vs. price of $4.46 (13.6% below fair value)
Industry Position: 69.1% below the Biotechnology median (#190 of 1227)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
53GF Score
Get the complete analysis for SILO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
